5 Stocks Pushing The Drugs Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 40 points (0.3%) at 12,582 as of Friday, Nov. 16, 2012, 11:59 AM ET. The NYSE advances/declines ratio sits at 1,549 issues advancing vs. 1,392 declining with 99 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is down 0.1%. A company within the industry that fell today was Eli Lilly and Company ( LLY), up 0.9%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 7.8%, Gilead ( GILD), up 1.5% and Bristol-Myers Squibb Company ( BMY), up 1.6%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Dynavax Technologies Corporation ( DVAX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Dynavax Technologies Corporation is down $2.27 (-49.0%) to $2.36 on heavy volume Thus far, 23.3 million shares of Dynavax Technologies Corporation exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $2.22-$2.51 after having opened the day at $2.30 as compared to the previous trading day's close of $4.63.

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Dynavax Technologies Corporation has a market cap of $827.4 million and is part of the health care sector. The company has a P/E ratio of -14.5, below the S&P 500 P/E ratio of 17.7. Shares are up 39.5% year to date as of the close of trading on Thursday. Currently there are 4 analysts that rate Dynavax Technologies Corporation a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Dynavax Technologies Corporation as a sell. Among the areas we feel are negative, one of the most important has been unimpressive growth in net income over time. Get the full Dynavax Technologies Corporation Ratings Report now.

4. As of noon trading, AstraZeneca ( AZN) is down $0.77 (-1.7%) to $44.30 on average volume Thus far, 820,536 shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $44.17-$44.73 after having opened the day at $44.64 as compared to the previous trading day's close of $45.07.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases worldwide. AstraZeneca has a market cap of $56.7 billion and is part of the health care sector. The company has a P/E ratio of 6.2, below the S&P 500 P/E ratio of 17.7. Shares are down 2.6% year to date as of the close of trading on Thursday. Currently there is 1 analyst that rates AstraZeneca a buy, 2 analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

3. As of noon trading, Sanofi ( SNY) is down $0.49 (-1.1%) to $42.24 on light volume Thus far, 612,770 shares of Sanofi exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $42.20-$42.93 after having opened the day at $42.88 as compared to the previous trading day's close of $42.73.

Sanofi, together with its subsidiaries, researches, develops, manufactures, and markets healthcare products worldwide. Sanofi has a market cap of $113.7 billion and is part of the health care sector. The company has a P/E ratio of 23.1, above the S&P 500 P/E ratio of 17.7. Shares are up 16.9% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate Sanofi a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

2. As of noon trading, Novartis ( NVS) is down $0.29 (-0.5%) to $58.68 on average volume Thus far, 1.2 million shares of Novartis exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $58.60-$59.17 after having opened the day at $59.16 as compared to the previous trading day's close of $58.97.

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Novartis has a market cap of $144.2 billion and is part of the health care sector. The company has a P/E ratio of 15.8, below the S&P 500 P/E ratio of 17.7. Shares are up 3.1% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Novartis a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Novartis Ratings Report now.

1. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is down $0.52 (-1.4%) to $38.10 on average volume Thus far, 1.2 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $38.05-$38.85 after having opened the day at $38.59 as compared to the previous trading day's close of $38.63.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $33.5 billion and is part of the health care sector. The company has a P/E ratio of 10.4, below the S&P 500 P/E ratio of 17.7. Shares are down 4.3% year to date as of the close of trading on Thursday. Currently there are 18 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Teva Pharmaceutical Industries Ratings Report now.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Acadia, Dynavax Make the Biotech Mailbag

Acadia, Dynavax Make the Biotech Mailbag